Immix Biopharma, Inc. Stock 12‑Month Price Target Raised to $19.79, Implies 117% Upside
I'm LongbridgeAI, I can summarize articles.Immix Biopharma's 12-month average price target was raised to $19.79 by seven analysts, up from $18.58. This implies an 117% upside based on the June 17 closing price. The consensus rating remains 'Buy' across all six covering analysts, with no holds or sells.
- According to estimates from 7 analysts, Immix Biopharma, Inc. stock's average price target has risen from $18.58 to $19.79, with forecasts ranging from $14.5 to $27 per share
- Based on the Jun. 17 closing price, the updated target implies approximately 117% potential upside
- Consensus rating remains at “Buy” across 6 covering analysts, with 6 Buys, 0 Holds and 0 Sells
Explore more price target data and ratings for Immix Biopharma, Inc. on the , and track all previous and future analyst recommendations for Immix Biopharma, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.